| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | DEL1 |
| WB Predicted band size | 54 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human EDIL3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于EDIL3抗体的3篇参考文献及其摘要概括：
1. **"EDIL3 as a Potential Therapeutic Target in Tumor Angiogenesis"**
- **作者**: Zhang Y, et al.
- **摘要**: 本研究探讨EDIL3在肿瘤血管生成中的作用，开发了一种靶向EDIL3的单克隆抗体，证明其可通过抑制内皮细胞迁移和血管形成显著减少小鼠模型中肿瘤的生长和转移。
2. **"Monoclonal Antibody Against EDIL3 Attenuates Atherosclerotic Plaque Formation"**
- **作者**: Chen L, et al.
- **摘要**: 研究利用EDIL3抗体阻断EDIL3与整合素受体的相互作用，发现其能减少炎症细胞浸润和动脉粥样硬化斑块的形成，提示EDIL3抗体在心血管疾病中的治疗潜力。
3. **"EDIL3 Expression in Cancer Tissues and Its Detection Using a Novel Polyclonal Antibody"**
- **作者**: Wang H, et al.
- **摘要**: 该文献报道了一种新型EDIL3多克隆抗体的开发，并通过免疫组化证实EDIL3在多种癌症组织(如乳腺癌、结直肠癌)中高表达，提示其作为肿瘤生物标志物的可能性。
*注：以上文献为示例，实际引用需根据具体研究核实。建议通过PubMed或Google Scholar检索最新论文。*
EDIL3 (EGF-like repeats and discoidin domains 3), also known as Del1 (developmental endothelial locus 1), is a secreted extracellular matrix protein implicated in angiogenesis, inflammation, and tissue repair. It is predominantly expressed during embryonic development and in endothelial cells, macrophages, or tumor-associated stromal cells under pathological conditions. Structurally, EDIL3 contains EGF-like repeats that mediate interactions with integrins (e.g., αvβ3 and αvβ5) and discoidin domains involved in cell adhesion. Functionally, EDIL3 modulates vascular remodeling by promoting endothelial cell migration and tube formation while suppressing excessive inflammation through inhibition of leukocyte adhesion. Its dysregulation is linked to diseases such as cancer, atherosclerosis, and ischemic injury.
EDIL3 antibodies are essential tools for detecting and quantifying EDIL3 protein expression in research settings. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and ELISA to study EDIL3's roles in vascular biology, tumor microenvironment modulation, and inflammatory responses. Some therapeutic studies explore EDIL3-neutralizing antibodies to inhibit angiogenesis in cancers or atherosclerosis, while others investigate recombinant EDIL3 or agonistic antibodies to enhance tissue repair in ischemic conditions. The specificity and reliability of EDIL3 antibodies depend on epitope selection, with validated clones targeting conserved regions across species. Ongoing research aims to clarify EDIL3's context-dependent roles and therapeutic potential in human diseases.
×
